China Animal Vaccine Industry Report, 2013-2016
  • June 2014
  • Hard Copy
  • USD $2,700
  • Pages:138
  • Single User License
    (PDF Unprintable)       
  • USD $2,500
  • Code: HK045
  • Enterprise-wide License
    (PDF Printable & Editable)       
  • USD $3,900
  • Hard Copy + Single User License
  • USD $2,900

Animal vaccine is a kind of biological agent that enables inoculated animals to produce active immunity for disease prevention. Europe and the United States and other developed countries are the main force of traditional animal vaccine markets in the world, still taking around 60% nowadays. In recent years, European and American animal vaccine markets have decelerated growth due to quality safety, high maturity and other factors, while the fast-growing animal vaccine market of China and other emerging countries will become a new highlight.

In 2004-2013, Chinese animal vaccine market size maintained a high growth rate of 26.3%, reaching about RMB11.5 billion in 2013. The growth in 2007-2010 was mainly driven by the expansion of governmental tender vaccine, while that from 2011 was primarily thanks to the market-oriented vaccine expansion. The Chinese animal vaccine market is basically occupied by local companies, showing a self-sufficiency rate of around 90%.

Given the policy factor, Chinese animal vaccine products are divided into compulsory immunization vaccines and market-oriented vaccines. At present, the former include foot-and-mouth disease (FMD), bird flu, porcine reproductive and respiratory syndrome (PRRS), swine fever, and peste des petits ruminants (PPR); the latter refer to porcine circovirus (PCV), Newcastle disease, porcine parvovirus (PPV) and other varieties. Since 2011, the bids for compulsory vaccines proposed by the Chinese government has turned to be more fierce, with limited growth potential; however, market-oriented vaccines have developed faster, enjoying 40%-50% market share in 2013.

According to animal attributes, animal vaccines can be classified into swine vaccines, poultry vaccines, cattle & sheep vaccines, pet vaccines and other vaccines. In 2013, Chinese swine vaccines and poultry vaccines accounted for more than 80% of the animal vaccine market. In addition, the emerging Chinese pet industry is boosting the demand for pet vaccines, but due to lack of commercialized pet vaccines, China now mainly relies on imports. Thus, the Chinese pet vaccine market will see a larger space for development in the future.

As the scale of Chinese farming escalates, the demand for animal vaccines will continue to grow steadily. In the next few years, the Chinese animal vaccine industry is expected to keep a growth rate of approximately 15% and see market value of RMB17.5 billion or so in 2016.

In 2006, China implemented mandatory veterinary drug GMP certification to raise the threshold, resulting in a sharp decline in the number of animal vaccine companies and the accompanying increased industry concentration. In 2013, CAHIC seized the highest market share of 10.5% among Chinese listed animal vaccine companies, followed by Jinyu Group, Tecon and Dahuanong with a combined proportion of 15% or so.

动物疫苗 英文_副本.jpg

China Animal Vaccine Industry Report, 2013-2016 by ResearchInChina covers the followings:
20120114.gifThe market size, market structure and competitive landscape of the global animal vaccine industry;
20120114.gifThe market size, market structure, competitive landscape and import & export of the Chinese animal vaccine industry;
20120114.gifPolicies, social environment and downstream demand of the Chinese animal vaccine industry;
20120114.gifThe size and competitive landscape of Chinese animal vaccine market segments such as swine vaccines and poultry vaccines;
20120114.gifOperation, animal vaccine business, forecast and outlook of 10 Chinese animal vaccine manufacturers;
20120114.gifThe market size and market structure of Chinese animal vaccine market and its segments in 2013-2016E.

1. Overview of Animal Vaccine
1.1 Definition
1.2 Classification
1.3 Industry Chain

2. Status Quo of Animal Vaccine Industry
2.1 Global Market
2.1.1 Market Size
2.1.2 Market Structure
2.1.3 Competitive Landscape
2.1.4 New Epidemics and Products
2.2 Chinese Market
2.2.1 Market Size
2.2.2 Market Structure
2.2.3 Import and Export
2.2.4 Profit 
2.2.5 Entry Barriers
2.2.6 Competitive Landscape
2.2.7 Trends

3. Development Environment for China Animal Vaccine Industry 
3.1 Policy Environment
3.1.1 Major Policies
3.1.2 Tendering System for Compulsory Immunization Vaccine 
3.2 Social Environment
3.2.1 Stable Development of Farming Industry
3.2.2 Large-scale Farming Becomes a Trend
3.2.3 Frequent Outbreaks of Animal Epidemics

4. Chinese Animal Vaccine Industry Segments 
4.1 Governmental Mandatory Vaccine  
4.1.1 FMD Vaccine 
4.1.2 Bird Flu Vaccine 
4.1.3 PRRS Vaccine 
4.1.4 Swine Fever Vaccine 
4.2 Market-oriented Vaccine 
4.2.1 PCV Vaccine 
4.2.2 Newcastle Disease Vaccine 
4.3 Pet Vaccine

5. Key Enterprises
5.1 CAHIC 
5.1.1 Profile
5.1.2 Operation 
5.1.3 Revenue Structure 
5.1.4 Gross Margin 
5.1.5 R & D 
5.1.6 Animal Vaccine Business 
5.1.7 Forecast and Outlook
5.2 Jinyu Group 
5.2.1 Profile
5.2.2 Operation 
5.2.3 Revenue Structure 
5.2.4 Gross Margin 
5.2.5 R & D 
5.2.6 Animal Vaccine Business 
5.2.7 Forecast and Outlook
5.3 Tecon
5.3.1 Profile
5.3.2 Operation 
5.3.3 Revenue Structure 
5.3.4 Gross Margin 
5.3.5 R & D 
5.3.6 Clients and Suppliers 
5.3.7 Animal Vaccine Business 
5.3.8 Forecast and Outlook
5.4 Tech-bank
5.4.1 Profile
5.4.2 Operation 
5.4.3 Revenue Structure 
5.4.4 Gross Margin 
5.4.5 R & D 
5.4.6 Animal Vaccine Business 
5.4.7 Forecast and Outlook
5.5 Shenghua Biok 
5.5.1 Profile
5.5.2 Operation 
5.5.3 Revenue Structure 
5.5.4 Gross Margin 
5.5.5 Clients 
5.5.6 Animal Vaccine Business 
5.5.7 Forecast and Outlook
5.6 Ringpu Bio-technology 
5.6.1 Profile
5.6.2 Operation 
5.6.3 Revenue Structure 
5.6.4 Gross Margin 
5.6.5 R & D 
5.6.6 Animal Vaccine Business 
5.6.7 Forecast and Outlook
5.7 Dahuanong 
5.7.1 Profile
5.7.2 Operation 
5.7.3 Revenue Structure 
5.7.4 Gross Margin 
5.7.5 R & D 
5.7.6 Animal Vaccine Business 
5.7.7 Forecast and Outlook
5.8 Hile Bio 
5.8.1 Profile
5.8.2 Operation 
5.8.3 Revenue Structure 
5.8.4 Gross Margin 
5.8.5 R & D 
5.8.6 Clients and Suppliers 
5.8.7 Animal Vaccine Business 
5.8.8 Forecast and Outlook
5.9 Yikang 
5.9.1 Profile
5.9.2 Operation 
5.9.3 Revenue Structure 
5.9.4 Gross Margin 
5.9.5 R & D 
5.9.6 Clients and Suppliers 
5.9.7 Animal Vaccine Business 
5.10 Chopper 
5.10.1 Profile
5.10.2 Operation 
5.10.3 Revenue Structure 
5.10.4 Gross Margin 
5.10.5 R & D 
5.10.6 Clients and Suppliers 
5.10.7 Animal Vaccine Business 

6. Summary and Forecast
6.1 Summary
6.2 Development Forecast
6.2.1 Swine Vaccine
6.2.2 Poultry Vaccine
6.2.3 Cattle and Sheep Vaccine
6.2.4 Pet Vaccine
Classification of Animal Health Products
Animal Vaccine Types (by Constituent and Feature) and Characteristics
Animal Vaccine Industry Chain
Classification of Animal Epidemics in China
Global Animal Vaccine Market Size, 2008-2016E
Profile of Global Animal Health Products Giants
Commercialized Vaccines and Manufacturers in Overseas Market in Recent Years
Development Process of Chinese Compulsory Vaccination Policies
Chinese Animal Vaccine Market Size, 2004-2013
China’s Animal Vaccine Net Import Value and Dependence on Export, 2008-2013
China’s Animal Vaccine Product Structure (by Animal Species), 2010-2013
China’s Animal Vaccine Product Structure (by Vaccine Type), 2010-2013
China’s Animal Vaccine Import and Export Volume, 2009-2014
China’s Average Animal Vaccine Import and Export Prices, 2009-2014
China’s Animal Vaccine Import Sources (by Import Volume), 2013
China’s Animal Vaccine Export Destinations (by Export Volume), 2013
Main Regions Which Import Animal Vaccines and Their Share in Import Volume in China, 2013
Main Regions Which Export Animal Vaccines and Their Share in Export Volume in China, 2013
Gross Margin of Animal Vaccine Business of Major Listed Animal Vaccine Companies in China, 2011-2013 
Barriers to Entry into Animal Vaccine Industry in China
Major Chinese Animal Vaccine Manufacturers and Their Capacity, 2013
Competitive Landscape of China Animal Vaccine Industry, 2013
Gap between Chinese Vaccine Production Process and International Advanced Level
Sino-foreign Joint Animal Vaccine Enterprises, 1990-2013
Major Polices on China Animal Vaccine Industry, 2010-2014
Compulsory Immunization Plan of Animal Epidemics in China, 2013
Animal Diseases worth Priority Prevention in China, 2013-2020
Defects of Compulsory Vaccination Tender System in China
Direction for Compulsory Vaccination Tender System Reform in China
Output of Meat, Eggs and Milk in China, 2009-2013
China’s Meat Product Structure (by Output), 2011-2013
Farming Scale Degree in China, 2010-2020E
Overview of Common Animal Epidemics in China
Animal Epidemic Summary in China, 2013
China’s Animal Vaccine Market Structure (by Sales Method)
Competitive Landscape of Main Compulsory Immunization Vaccine Markets in China, 2013
Performance Comparison between Swine Fever Vaccines in China
Classification and Market Conditions of Market-oriented Vaccines in China
Market Capacity of Some Compulsory Market-oriented Vaccines in China, 2013
Market Capacity of Some Non-compulsory Vaccines in China, 2013
Market Capacity of Newcastle Disease Vaccine and Market Share of Ringpu Bio-technology
Pet Vaccine Suppliers in Chinese Market and Their Products
CAHIC’s Revenue and Net Income, 2009-2013
CAHIC’s Revenue (by Product), 2011-2013
CAHIC’s Revenue Structure (by Product), 2011-2013 
CAHIC’s Revenue (by Region), 2011-2013
CAHIC’s Revenue Structure (by Region), 2011-2013 
Gross Margin of CAHIC’s Main Products, 2011-2013  
CAHIC’s R & D Costs and % of Total Revenue, 2011-2013
CAHIC's Animal Vaccine Subsidiaries and Their Products 
CAHIC's Animal Vaccine Projects under Construction, 2014
CAHIC's Revenue and Net Income, 2012-2016E
Jinyu Group’s Revenue and Net Income, 2009-2013 
Jinyu Group’s Revenue (by Product), 2011-2013
Jinyu Group’s Revenue Structure (by Product), 2011-2013 
Jinyu Group’s Revenue (by Region), 2011-2013 
Jinyu Group’s Revenue Structure (by Region), 2011-2013 
Gross Margin of Jinyu Group’s Main Business, 2010-2013
Jinyu Group’s R & D Costs and % of Total Revenue, 2011-2013 
Animal Vaccine Subsidiaries of Jinyu Group, 2013
Revenue and Net Income of Spirit Jinyu, 2012-2013
Jinyu Group’s Revenue and Net Income, 2012-2016E
Tecon’s Revenue and Net Income, 2009-2013 
Tecon’s Revenue (by Product), 2011-2013
Tecon’s Revenue Structure (by Product), 2011-2013 
Tecon’s Revenue (by Region), 2011-2013 
Tecon’s Revenue Structure (by Region), 2011-2013 
Gross Margin of Tecon’s Main Products, 2011-2013  
Tecon’s R & D Costs and % of Total Revenue, 2011-2013
Tecon’s Revenue from Top 5 Clients and % of Total Revenue, 2011-2013
Name List and Revenue Contribution of Tecon’s Top 5 Clients, 2013
Tecon’s Procurement from Top 5 Suppliers and % of Total Procurement, 2011-2013
Name List and Procurement Contribution of Tecon’s Top 5 Suppliers, 2013
Tecon’s Animal Vaccine Production Bases and Capacity, 2013
Tecon’s Revenue and Net Income, 2012-2016E
Tech-bank’s Revenue and Net Income, 2009-2013 
Tech-bank’s Revenue (by Product), 2011-2013
Tech-bank’s Revenue Structure (by Product), 2011-2013 
Tech-bank’s Revenue (by Region), 2011-2013 
Tech-bank’s Revenue Structure (by Region), 2011-2013 
Tech-bank’s Gross Margin of Main Products, 2011-2013  
Tech-bank’s R & D Costs and % of Total Revenue, 2011-2013
Revenue and Net Income of Chengdu TECBOND, 2010-2013
Tech-bank’s Revenue and Net Income, 2012-2016E
Shenghua Biok’s Revenue and Net Income, 2009-2013 
Shenghua Biok’s Revenue (by Product), 2011-2013
Shenghua Biok’s Revenue Structure (by Product), 2011-2013 
Shenghua Biok’s Revenue (by Region), 2011-2013 
Shenghua Biok’s Revenue Structure (by Region), 2011-2013 
Gross Margin of Shenghua Biok’s Main Products, 2011-2013
Shenghua Biok’s Revenue from Top 5 Clients and % of Total Revenue, 2011-2013 
Name List and Revenue Contribution of Shenghua Biok’s Top 5 Clients, 2013  
Revenue and Net Income of Qingdao Yebio, 2009-2013
Shenghua Biok’s Revenue and Net Income, 2012-2016E
Ringpu Bio-technology’s Revenue and Net Income, 2009-2013 
Ringpu Bio-technology’s Revenue (by Product), 2011-2013
Ringpu Bio-technology’s Revenue Structure (by Product), 2011-2013 
Ringpu Bio-technology’s Revenue (by Region), 2012-2013 
Ringpu Bio-technology’s Revenue Structure (by Region), 2012-2013 
Ringpu Bio-technology’s Gross Margin of Main Products, 2011-2013  
Ringpu Bio-technology’s R & D Costs and % of Total Revenue, 2011-2013 
Ringpu Bio-technology’s Animal Vaccine Output and Sales Volume (by Product), 2011-2013
Sales and Gross Margin of Ringpu Bio-technology’s Animal Vaccines (by Product), 2013
Ringpu Bio-technology’s Animal Vaccine Subsidiaries and Their Products, 2013
Revenue and Net Income of Ringpu Bio-technology’s Animal Vaccine Subsidiaries, 2013 
Ringpu Bio-technology’s Animal Vaccine Projects under Construction, 2013
Ringpu Bio-technology’s Revenue and Net Income, 2012-2016E  
Dahuanong’s Revenue and Net Income, 2009-2013 
Dahuanong’s Revenue Structure (by Product), 2011-2013
Dahuanong’s Revenue Structure (by Product), 2011-2013
Dahuanong’s Revenue (by Region), 2011-2013
Dahuanong’s Revenue Structure (by Region), 2011-2013
Gross Margin of Dahuanong’s Main Products, 2011-2013
Dahuanong’s R & D Costs and % of Total Revenue, 2011-2013
Capacity of Dahuanong’s Animal Vaccine Products, 2010-2013  
Output, Sales Volume and Sales-output Ratio of Dahuanong’s Veterinary Biologics, 2012-2013
Dahuanong’s Revenue and Net Income, 2012-2016E  
Hile Bio’s Main Products
Hile Bio’s Revenue and Net Income, 2011-2013
Hile Bio’s Revenue Structure (by Product), 2011-2013
Hile Bio’s Revenue Structure (by Product), 2011-2013
Hile Bio’s Revenue (by Region), 2011-2013 
Hile Bio’s Revenue Structure (by Region), 2011-2013
Gross Margin of Hile Bio’s Main Products, 2011-2013
Hile Bio’s R & D Costs and % of Total Revenue, 2011-2013
Name List and Revenue Contribution of Hile Bio’s Top 5 Clients, 2013
Hile Bio’s Procurement from Top 5 Suppliers and % of Total Procurement, 2011-2013 
Name List and Procurement Contribution of Hile Bio’s Suppliers, 2013
Hile Bio’s Revenue Structure (by Product), 2013
Hile Bio’s Revenue Structure (by Sales Method), 2011-2013
Hile Bio’s Swine Vaccine Capacity, Output and Sales Volume, 2011-2013
Selling Prices of Hile Bio’s Main Products, 2011-2013   
Hile Bio’s Animal Vaccine Fundraising Projects, 2014 
Hile Bio’s Revenue and Net Income, 2012-2016E  
Yikang’s Revenue and Net Income, 2009-2011 
Yikang’s Revenue Structure (by Product), 2009-2011
Yikang’s Revenue Structure (by Product), 2009-2011
Yikang’s Revenue (by Region), 2009-2011 
Yikang’s Revenue Structure (by Region), 2009-2011
Gross Margin of Yikang’s Main Products, 2009-2011
Yikang’s R & D Costs and % of Total Revenue, 2009-2011 
Yikang’s Revenue from Top 5 Clients and % of Total Revenue, 2009-2011
Name List and Revenue Contribution of Yikang’s Top 5 Clients, 2011
Yikang’s Procurement from Top 5 Suppliers and % of Total Procurement, 2009-2011
Name List and Procurement Contribution of Yikang’s Suppliers, 2011
Yikang’s Animal Vaccine Production Lines, 2009-2011
Yikang’s Capacity, Output and Capacity Utilization, 2009-2011 
Yikang’s Output, Sales Volume and Sales-output Ratio, 2009-2011 
Average Selling Price of Yikang’s Main Products, 2009-2011
Yikang’s Revenue Structure (by Sales Method), 2009-2011
Chopper’s Revenue and Net Income, 2009-2011 
Chopper’s Revenue (by Product), 2011-2013
Chopper’s Revenue Structure (by Product), 2011-2013
Chopper’s Revenue (by Region), 2011-2013 
Chopper’s Revenue Structure (by Region), 2011-2013
Sales of Chopper's Main Vaccine Products, 2011-2013
Chopper’s R & D Costs and % of Total Revenue, 2011-2013
Chopper’s Revenue from Top 5 Clients and % of Total Revenue, 2011-2013
Name List and Revenue Contribution of Chopper’s Top 5 Clients, 2013
Chopper’s Procurement from Top 5 Suppliers and % of Total Procurement, 2011-2013
Name List and Procurement Contribution of Chopper’s Suppliers, 2013
Chopper’s Products and Clients (by Sales Method)
Chopper’s Sales Structure by Sales Method, 2011-2013
Sales of Chopper’s Main Vaccine Products, 2011-2013
Chopper’s Sales Structure by Main Vaccine Product, 2011-2013
Chopper’s Vaccine Capacity, Output and Capacity Utilization, 2011-2013
Chopper’s Vaccine Output, Sales Volume and Sales-output Ratio, 2011-2013
Average Selling Price of Chopper’s Main Vaccine Products, 2011-2013
Chopper’s Investment Plan, 2014
Animal Vaccine Revenue of Major Animal Vaccine Companies in China, 2011-2013 
Chinese Animal Vaccine Market Size, 2012-2016E
Chinese Animal Vaccine Market Structure (by Animal Attributes), 2013 vs 2016E 
Chinese Swine Vaccine Market Size, 2012-2016E
Chinese Poultry Vaccine Market Size, 2012-2016E

China Vacuum Blood Collection Industry Report, 2014-2017

The vacuum blood collection system consisting of vacuum blood collection tubes, disposable blood collection needles, tourniquets, etc transfers human venous blood to closed containers and makes it int...

China Pharmaceutical Excipients Industry Report, 2014-2017

Pharmaceutical excipients refer to adjuvants and additives used for production of pharmaceuticals and compounding of prescriptions. In addition to active ingredients, pharmaceutical excipients are als...

China Recombinant Protein Drug Industry Report, 2014-2017

The Chinese recombinant protein drug market has been expanding rapidly owing to the improvement of demand rigidity, consumption ability and the like. During 2005-2013, sales of recombinant protein dru...

China Heparin Industry Report, 2014-2017

As the world's major heparin API producer and exporter, China boasts enormous raw materials, which provides a strong support for the production of China’s heparin products. In 2013, the live pigs rais...

Global and China Monoclonal Antibody Industry Report, 2014-2019

Despite world-wide economic downturn and great changes in exchange rate, benefiting from robust market demand, global monoclonal antibody market size exceeded USD 80 billion in 2013, still one of biot...

Global and China DNA Sequencing Industry Research Report, 2014-2017

DNA sequencing is the process of reading nucleotide bases in a specific DNA molecule, that is to say determining the arrangement mode of adenine, thymine, cytosine, and guanine. It can be applied in a...

Global and China Stem Cell Industry Report, 2014-2017

Stem cells are undifferentiated biological cells that can differentiate into specialized cells and can divide (through mitosis) to produce more stem cells. Stem cell therapy can be applied to treatmen...

China Human Vaccine Industry Report, 2014-2017

Vaccines can prevent and control infectious diseases, so the demand for these biological products is relatively rigid. In 2013, China’s human vaccine lot release volume grew by 4.9% from a year earlie...

China Blood Product Industry Report, 2014-2017

Plasma resource reserves and control are crucial to the development of blood products industry. Although the closure of 16 plasma collection stations in Guizhou in 2011 didn’t cause major disruption t...

China Animal Vaccine Industry Report, 2013-2016

Animal vaccine is a kind of biological agent that enables inoculated animals to produce active immunity for disease prevention. Europe and the United States and other developed countries are the main ...

China Contract Research Organization (CRO) Industry Report, 2013-2016

China CRO industry has developed rapidly in recent years, registering a CAGR of 27.2% during 2007-2013, of which the market size reached RMB 36 billion in 2013, occupying 10% of global market share. ...

Global and China Biodegradable Plastics Industry Report, 2013-2016

Global biodegradable plastic production and demand have grown rapidly in recent years, and the capacity reached 1-1.5 million t/a in 2012-2013. Among dozens of biodegradable plastic varieties develope...

Global and China Industrial Enzyme Industry Report, 2014-2016

In 2007-2013, the global industrial enzyme market size grew at the CAGR of 5.7%, reaching USD4.04 billion in 2013, 1.4 times that in 2007. The global industrial enzyme market is monopolized by a small...

China Heparin Industry Report, 2013-2015

Since the small intestines of pigs (raw materials for production of heparin) in China are abundant (the pig slaughtering volume in China approximates 50% of globe’s total) and heparin APIs are gradual...

China Lactic Acid and Derivative Industry Report, 2013

China’s lactic acid capacity and output continued to grow at the respective CAGR of 22.7% and 28.7% in 2007-2011. But limited by market demand, the annual output of most vendors was below their design...

China Human Vaccine Industry Report, 2012-2015

In the wake of China's economic growth and enhanced disease prevention awareness, Chinese human vaccine market has been expanding. In 2012, Chinese human vaccine market valued RMB10.5 billion with the...

China Blood Product Industry Report, 2012-2015

Plasma is a key raw material of the blood product industry. In August 2011, China shut down 16 plasma stations in Guizhou, resulting in a decrease of 15% in the plasma volume of the year. However, due...

China Animal Vaccine Industry Report, 2012-2015

In view of the frequent occurrence of animal epidemic diseases over the years, the Chinese government has increased investment in epidemic prevention and implemented compulsory immunization system. Be...

2005-2014 All Rights Reserved 京ICP备05069564号-1 京公网安备1101054484号